Sanofi Wants Antitrust Claims Over Insulin Pen Pared Down
Sanofi-Aventis is trying to knock out a recently revived antitrust suit accusing it of improperly putting one of its insulin injector patents on an FDA list, which allowed the pharmaceutical company...To view the full article, register now.
Already a subscriber? Click here to view full article